Taysha Gene Therapies, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TSHA Nasdaq 2836 www.tayshagtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Taysha Gene Therapies, Inc.

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - Aug 18th, 2026 5:13 pm
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Aug 13th, 2026 8:09 am
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 6:30 am
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Aug 11th, 2026 11:02 pm
Taysha Gene Therapies Q2 Earnings Call Highlights - Aug 11th, 2026 7:04 pm
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 11th, 2026 2:00 pm
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 7th, 2026 6:00 am
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - Aug 4th, 2026 2:00 pm
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Aug 3rd, 2026 6:00 am
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In - Jul 15th, 2026 8:01 am
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run - Jul 12th, 2026 12:15 pm
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - Jun 25th, 2026 2:01 pm
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Jun 24th, 2026 8:33 pm
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jun 24th, 2026 2:01 pm
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA) - Jun 22nd, 2026 6:56 am
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome - Jun 22nd, 2026 6:00 am
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery - Jun 13th, 2026 6:12 am
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Jun 11th, 2026 12:00 pm